A

Allogene Therapeutics
D

ALLO

1.68500
USD
-0.04
(-2.32%)
مغلق
حجم التداول
252,252
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
582,152,134
المقالات
المزيد

العنوان: Allogene Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).